Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Hepatic Encephalopathy

In brief

Study RNLC3132 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.

Key facts

Study ID
NCT05297448
Run by
Bausch Health Americas, Inc.
People needed
466
Starts
2022-08-03
Expected to finish
2026-01-01
Last updated by the study team
2025-09-10

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.